Pfizer granted FDA fast-track designation within NASH indication

This type of non-alcoholic fatty liver disease has no current treatments approved in the US, but Pfizer is now gearing up to get a medicine on the market.
by christopher due karlsson, translated by daniel pedersen

US-based Pfizer can now ramp up development efforts for its combination treatment against non-alcoholic steatohepatitis (NASH) with liver fibrosis, a type of non-alcoholic fatty liver disease, as the US Food and Drug Administration (FDA) has decided to fast-track the firm’s treatment candidate, Pfizer has announced in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading